Journal
NEUROPHARMACOLOGY
Volume 61, Issue 3, Pages 364-381Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2011.01.017
Keywords
Hallucinogen; LSD; Psilocybin; Serotonin; Drug discrimination; Locomotor activity; Head twitch; 5-HT1A receptor
Categories
Funding
- National Institute on Drug Abuse [R01DA002925, F32DA025412]
- Veterans Affairs, Mental Illness Research, Education, and Clinical Center [VISN 22]
Ask authors/readers for more resources
Serotonergic hallucinogens produce profound changes in perception, mood, and cognition. These drugs include phenylalkylamines such as mescaline and 2,5-dimethoxy-4-methylamphetamine (DOM), and indoleamines such as (+)-lysergic acid diethylamide (LSD) and psilocybin. Despite their differences in chemical structure, the two classes of hallucinogens produce remarkably similar subjective effects in humans, and induce cross-tolerance. The phenylalkylamine hallucinogens are selective 5-HT2 receptor agonists, whereas the indoleamines are relatively non-selective for serotonin (5-HT) receptors. There is extensive evidence, from both animal and human studies, that the characteristic effects of hallucinogens are mediated by interactions with the 5-HT2A receptor. Nevertheless, there is also evidence that interactions with other receptor sites contribute to the psychopharmacological and behavioral effects of the indoleamine hallucinogens. This article reviews the evidence demonstrating that the effects of indoleamine hallucinogens in a variety of animal behavioral paradigms are mediated by both 5-HT2 and non-5HT(2) receptors. This article is part of a Special Issue entitled 'Serotonin: The New Wave'. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available